|Bid||4.0000 x 0|
|Ask||4.0600 x 0|
|Day's Range||4.0000 - 4.2500|
|52 Week Range||0.5400 - 9.0000|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
, March 22, 2021 /CNW/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC). Unique to other recently published Y-90 studies, DOORwaY90, which stands for "Duration of Objective Response with Arterial Y-90," is the first prospective, multicenter study to utilize and delineate personalized dosimetry treatment planning and to define actionable post-treatment dosimetric verification for endpoint assessment.
6, 2021 /CNW/ - The Prime Minister, Justin Trudeau, today issued the following statement on the selection of the next premier of Nova Scotia:"On behalf of the Government of Canada, I congratulate Iain Rankin on his successful bid to become the leader of the Nova Scotia Liberal Party and the next premier of the province."I look forward to working closely with Mr.
We can readily understand why investors are attracted to unprofitable companies. For example, although...